Bioxyne Limited AI Stock Analysis
Want to see AU:BLS full AI Analyst Report?
Bioxyne Limited (BLS) AI Stock Analysis
Bioxyne Limited
(ASX:BLS)
Bioxyne Limited earns a very strong overall score driven primarily by a spectacular financial turnaround, featuring explosive revenue growth, high profitability, and a pristine balance sheet. This robust fundamental strength is complemented by highly bullish technical momentum across all major moving averages. Additionally, the stock's P/E ratio of 25.0 represents a reasonable valuation for a company demonstrating such rapid fundamental improvement.
Bioxyne Limited (BLS) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 201.84M
- Dividend Yield
- ―
- Average Volume (3M)
- 345.43K
- Price to Earnings (P/E)
- 23.1
- Beta (1Y)
- 1.90
- Revenue Growth
- 160.87%
- EPS Growth
- 188.14%
- Country
- Australia
- Employees
- 16
- Sector
- General
- Sector Strength
- 55
- Industry
- Specialty Business Services
Bioxyne Limited Business Overview & Revenue Model
Company Description
BLS Pharmaceuticals Ltd. engages in the research, development, market and distribution of health products. It operates through the following segments: Wholesale, Plant Based, and Direct Sales. The Wholesale segment covers operation in United States o...
How the Company Makes Money
Bioxyne generates revenue primarily from medicinal cannabis-related activities, including (where permitted under applicable regulation) sales of cannabis products and/or cannabis-derived formulations, and fees or margins associated with distributing...
Bioxyne Limited Financial Statement Overview
Summary
Bioxyne Limited exhibits an extraordinary financial turnaround with 77% revenue growth, a stellar 42% Return on Equity (ROE), and over 3400% free cash flow growth. The balance sheet is exceptionally strong with minimal debt.
Income Statement
92Very PositiveBalance Sheet
94Very PositiveCash Flow
93Very PositiveBioxyne Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BLS, the sentiment is Negative. The current price of 0.85 is below the 20-day moving average (MA) of 0.95, below the 50-day MA of 1.04, and above the 200-day MA of 0.82, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 36.25 is Neutral, neither overbought nor oversold. The STOCH value of 20.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BLS.
Bioxyne Limited Peers Comparison
Overall Rating
- AU:BLS89Outperform
AU:CLV77Outperform
AU:BUB48Neutral
AU:NGS46Neutral
AU:NUC37Underperform
AU:HCT29Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:BLS | 89Outperform | AUD 201.84M | 23.09 | 56.29% | ― | 160.87% | 188.14% |
| AU:CLV | 77Outperform | AUD 170.34M | 16.29 | 13.83% | 2.45% | 13.26% | 49.05% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| AU:BUB | 48Neutral | AUD 70.72M | -15.19 | -11.08% | ― | 9.08% | -183.87% |
| AU:NGS | 46Neutral | AUD 19.28M | -0.01 | -130.72% | ― | -33.05% | 94.22% |
| AU:NUC | 37Underperform | AUD 9.57M | -1.28 | -88.51% | ― | 11.96% | -81.99% |
| AU:HCT | 29Underperform | AUD 12.14M | -3.79 | 1795.70% | ― | 0.72% | -486.96% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:BLS | Bioxyne Limited | 0.85 | 0.48 | 131.08% | |
| AU:BUB | Bubs Australia Ltd. | 0.08 | -0.06 | -43.57% | |
| AU:NUC | Nuchev Pty Ltd | 0.06 | -0.10 | -63.03% | |
| AU:HCT | Holista Colltech Limited | 0.03 | -0.06 | -63.33% | |
| AU:NGS | Nutritional Growth Solutions Ltd. | 0.02 | 0.00 | 5.26% | |
| AU:CLV | Clover Corporation Limited | 1.02 | 0.38 | 58.14% |
Bioxyne Limited Corporate Events
BLS Pharmaceuticals to Outline Growth Strategy at Coffee Microcaps Forum
BLS Pharmaceuticals Limited will present at the Coffee Microcaps Morning Meeting on 31 July 2026, where Executive Director and COO Jason Hine is set to outline the company’s June quarter results, recent operational milestones and its broader growth s...
BLS Pharmaceuticals Updates Investors Ahead of Q4 FY2026 Results Webinar
BLS Pharmaceuticals Limited has released an updated investor presentation ahead of its Q4 FY2026 results webinar scheduled for 31 July 2026. The presentation and subsequent recording will provide investors with detailed insights into the company’s re...
BLS Pharmaceuticals to Brief Investors on Q4 FY2026 Results in Upcoming Webinar
BLS Pharmaceuticals Limited will host an investor webinar on 31 July 2026 to discuss its June quarter FY2026 results, recent operational highlights and growth strategy. The session, led by CEO and Managing Director Sam Watson, will include a presenta...
BLS Pharmaceuticals to Commercialise Trexapharm’s TREXAVIVE Neurotherapy in Australia
BLS Pharmaceuticals has entered a non-binding Heads of Agreement with Trexapharm to become the preferred commercial partner in Australia for TREXAVIVE, a proprietary neurotherapy targeting treatment-resistant depression and related disorders. The col...
BLS Pharmaceuticals Expands Global Psychedelic Medicines Reach via Cayman Partnership
BLS Pharmaceuticals has entered an international referral agreement with Cayman Chemical Company, under which Cayman will direct global customers seeking finished MDMA and psilocybin dosage forms to BLS. The deal, which complements an existing API su...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jun 24, 2026